ClinicalTrials.gg
Not yet recruitingNCT05964790Updated Jul 28, 2023

Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia

A Phase 1/2 interventional study of HS-10380 and Placebo in Schizophrenia, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10380 relative to placebo for the treatment of participants with schizophrenia.

Read the detailed description

The trial consists of two parts: dose escalation cohorts and expansion cohorts. The primary aim of the dose escalation cohorts is to evaluate the safety and tolerability of HS-10380 in participants with schizophrenia, and the primary aim of expansion cohorts is to evaluate efficacy of HS-10380 in participants with schizophrenia.

02

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Psychotropic drug
  • Antipsychotic agents
03

In context

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

This study's planned enrollment of 112 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dose escalation cohorts:

    1. Patients are 18 to 55 years of age, inclusive.
    2. (BMI) between 18.5 and 30.0 kg/m2 ,inclusive. Weight ≥ 50 kg for male subjects and ≥ 45 kg for female subjects.
    3. Patient meets criteria for schizophrenia.
    4. Currently not taking antipsychotics. Or on a stable dose of single second-generation antipsychotics (SGA) for at least 2 weeks, limited to either risperidone, olanzapine, quetiapine, aripiprazole, or paliperidone.
    5. PANSS total score ≤ 90. Rating ≤ 4 on hostility and uncooperativeness,
    6. Negative urine pregnancy test (women of only).
    7. Male and female patients must agree to use a highly effective method of during the course of the entire study and for 3 months after the last dose of product.
    8. Written has been obtained.

Expansion cohorts:

  1. Patients are 18 to 65 years of age, inclusive.
  2. Patient meets DSM-5 criteria for schizophrenia.
  3. No current use of antipsychotics. Or withdrawing from antipsychotics other than clozapine for more than 5 half-lives prior to randomization.
  4. PANSS total score ≥70 and ≤120. Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms; P1: delusions; P2: conceptual disorganization; P3: hallucinatory behavior; P6: suspiciousness/persecution.
  5. Negative urine pregnancy test (women of childbearing potential only).
  6. Male and female patients must agree to use a highly effective method of birth control during the course of the entire study and for 3 months after the last dose of investigational product.
  7. Written informed consent has been obtained.

Exclusion criteria

Exclusion Criteria:

  • Dose escalation cohorts:

    1. Patients meet criteria for a mental illness other than schizophrenia, and might interfere with the conduct of the study as determined by the investigator.
    2. Current risk of self-harm or violence, including: having any suicidal ideation or suicidal behavior within the last 6 months, as assessed using Columbia-Suicidal Severity Rating Scale (C-SSRS).
    3. Patients who have a neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorder, etc. Medical conditions that are minor or well-controlled may be considered acceptable if the condition does not interfere with the conduct of the study.
    4. Patients who received electroconvulsive therapy (ECT) within 3 months prior to screening.
    5. Received a long-acting antipsychotic within 6 months prior to screening or within the duration of 5 half-lives of the drug.
    6. History of seizure disorder (with the exception of febrile seizure).
    7. History of malignant syndrome.
    8. Any condition that would be expected to affect drug absorption, distribution, metabolism and excretion, including gastrointestinal surgery, urinary tract obstruction or difficulty in urination, etc.
    9. History of severe allergies.
    10. Female patients who are pregnant, puerperal or breastfeeding.
    11. History of drug addiction within 1 year prior to screening.
    12. Patients who has a history of alcohol abuse (defined as more than 14 standard units of alcohol consumption per week, 1 standard unit = 360 mL of beer, 45 mL of distilled spirits or 150 mL of wine) within 6 months prior to screening, or are unable to abstain from alcohol use during the study period.
    13. Patients who smoke ≥10 cigarettes per day within 3 months prior to screening, or are unable to quit smoking during the study period.
    14. Abnormal physical examination results that may interfere with the study.
    15. Abnormal vital signs that may interfere with the study, including: resting heart rate \<60 or >100 beats per minute, systolic blood pressure \<90mmHg or ≥140mmHg, diastolic blood pressure \<60mmHg or ≥90mmHg.
    16. Abnormal (ECG) results may interfere with the study, including: >450ms for male subjects and >470ms for female subjects based on Fridericia correction.
    17. Abnormal clinical laboratory test results may interfere with the study, including: (AST) or alanine aminotransferase (ALT) results >1.5 × the (ULN); serum prolactin levels >5 × ULN or significant clinical symptoms like amenorrhea, gynecomastia, and lactation.
    18. Patients whose results for surface antigen (HBsAg), antibody (HCV-Ab), antibody (HIV-Ab), or syphilis serological reaction (TRUST) is not negative.
    19. Blood donation or blood loss ≥ 200ml within 1 month prior to screening.
    20. Patients requiring concomitant treatment with a moderate or strong cytochrome P450 (CYP) 3A4 inhibitors or inducers, or a moderate or strong cytochrome CYP2D6 inhibitors or CYP3A4 inducers.
    21. Prior participation in any Interventional clinical trials within 3 months.
    22. Unsuitable for any other reason, as judged by the investigator.

Expansion cohorts:

  1. Patients meet DSM-5 criteria for a mental illness other than schizophrenia, and might interfere with the conduct of the study as determined by the investigator.
  2. Current risk of self-harm or violence, including: having any suicidal ideation or suicidal behavior within the last 6 months, as assessed using Columbia-Suicidal Severity Rating Scale (C-SSRS).
  3. Patients who have a clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorder, etc. Medical conditions that are minor or well-controlled may be considered acceptable if the condition does not interfere with the conduct of the study.
  4. Patients who received electroconvulsive therapy (ECT) within 3 months prior to screening.
  5. Received a long-acting antipsychotic within 6 months prior to screening or within the duration of 5 half-lives of the drug.
  6. History of seizure disorder (with the exception of febrile seizure).
  7. History of malignant syndrome.
  8. Any condition that would be expected to affect drug absorption, distribution, metabolism and excretion, including gastrointestinal surgery, urinary tract obstruction or difficulty in urination, etc.
  9. History of severe allergies.
  10. Female patients who are pregnant, puerperal or breastfeeding.
  11. History of drug addiction within 1 year prior to screening.
  12. Patients who has a history of alcohol abuse (defined as more than 14 standard units of alcohol consumption per week, 1 standard unit = 360 mL of beer, 45 mL of distilled spirits or 150 mL of wine) within 6 months prior to screening, or are unable to abstain from alcohol use during the study period.
  13. Abnormal physical examination results that may interfere with the study.
  14. Abnormal vital signs that may interfere with the study, including: resting heart rate \<60 or >100 beats per minute, systolic blood pressure \<90mmHg or ≥140mmHg, diastolic blood pressure \<60mmHg or ≥90mmHg.
  15. Abnormal electrocardiogram (ECG) results may interfere with the study, including: QTcF>450ms for male subjects and >470ms for female subjects based on Fridericia correction.
  16. Abnormal clinical laboratory test results may interfere with the study, including: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) results > 2 × the upper limit of normal (ULN).
  17. Patients whose results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or syphilis serological reaction (TRUST) is not negative.
  18. Patients requiring concomitant treatment with a moderate or strong cytochrome P450 (CYP) 3A4 inhibitors or CYP3A4 inducers, or a moderate or strong cytochrome CYP2D6 inhibitors or CYP3A4 inducers.
  19. Blood donation or blood loss ≥ 200ml within 1 month prior to screening.
  20. Prior participation in any Interventional clinical trials within 3 months.
  21. Unsuitable for any other reason, as judged by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    HS-10380

    Participants received HS-10380 tablet orally once daily for 28 days.

    Drug: HS-10380

  • Placebo comparator
    Placebo

    Participants received placebo tablet matching HS-10380 1.5mg tablet orally once daily for 28 days.

    Drug: Placebo

Interventions

  • Participants in arm HS-10380 will receiving multiple ascending doses of HS-10380 (1.5 mg initial dose) orally once daily for 28 days

  • DrugPlacebo

    Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days

06

What researchers measure

Primary outcomes

  1. Dose escalation cohorts: Incidence and severity of adverse events(AE) ,serious AEs and AE leading to withdrawal from treatment.

    An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect.

    Time frame: Baseline to Day 43

  2. Dose escalation cohorts: Changes from baseline in complete blood count (CBC).

    Hematology parameters to be reported: white blood cells, red blood cells and platelets.

    Time frame: Baseline to Day 36

  3. Dose escalation cohorts: Changes from baseline in urinalysis.

    Parameters to be reported: protein, glucose, ketones, red blood cells, and white blood cells.

    Time frame: Baseline to Day 36

  4. Dose escalation cohorts: Changes from baseline in blood biochemistry test.

    Parameters to be reported: glucose, urea, serum creatinine, alanine aminotransferase, aspartate transaminase, albumin, total protein, bilirubin, and blood lipid index.

    Time frame: Baseline to Day 36

  5. Dose escalation cohorts: Changes from baseline in coagulation function test.

    prothrombin time, activated partial thromboplastin time and international normalized ratio.

    Time frame: Baseline to Day 36

  6. Dose escalation cohorts: Changes from baseline in thyroid function test.

    thyroxine, triiodothyronine, free triiodothyronine, free thyroxin and thyroid stimulating hormone.

    Time frame: Baseline to Day 36

  7. Dose escalation cohorts: Changes from baseline in serum prolactin.

    Laboratory test.

    Time frame: Baseline to Day 36

  8. Dose escalation cohorts: Changes from baseline in blood pressure (BP).

    Vital sign.

    Time frame: Baseline to Day 36

  9. Dose escalation cohorts: Changes from baseline in pulse rate.

    Vital sign.

    Time frame: Baseline to Day 36

  10. Dose escalation cohorts: Changes from baseline in body temperature.

    Vital sign.

    Time frame: Baseline to Day 36

  11. Dose escalation cohorts: Change from baseline in body weight

    Body weight was measured in kilograms (Kg).

    Time frame: Baseline to Day 29

  12. Dose escalation cohorts: Change from baseline in Electrocardiogram (ECG)

    ECG parameters including heart rate, PR interval, RR interval and QTcF, etc.

    Time frame: Baseline to Day 36

  13. Dose escalation cohorts: Change from baseline in Simpson-Angus Scale (SAS)

    SAS is a 10-item testing instrument used to evaluate drug-related extrapyramidal syndromes. The following items are included in the SAS: gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella reflex, tremor, and salivation. Total score ranges from 0 to 40 with a higher score indicating increased severity.

    Time frame: Baseline to Day 36

  14. Change from baseline in Abnormal Involuntary Movement Scale (AIMS)

    AIMS is a rating scale measuring involuntary movements known as tardive dyskinesia, that sometimes develop as a side effect of long-term treatment with antipsychotic medications. The AIMS score was calculated as the sum of questions 1 through 7 of the AIMS instrument, which includes assessments of involuntary movements in the face, lips, jaw, tongue, upper and lower extremities, and neck/shoulders/hips. Each item is rated on a five-point scale of severity from 0-4 with 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Total scores range from 0 to 28.

    Time frame: Baseline to Day 36

  15. Dose escalation cohorts: Change from baseline in Barnes Akathisia Rating Scale

    BARS is a rating scale that is administered by physicians to assess the severity of drug-induced akathisia, which is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion, as well as by actions such as rocking while standing or sitting, lifting the feet as if marching on the spot, and crossing and uncrossing the legs while sitting. The following subcategories are scored: objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness and are rated on a 4-point scale from 0-3. In addition, the global clinical assessment of akathisia uses a 6-point scale ranging from 0-5. Total score ranges from 0 to 14 with a higher score indicating increased severity.

    Time frame: Baseline to Day 36

  16. Dose escalation cohorts: Change from Baseline in Columbia - Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a scale capturing occurrence, severity, and frequency of suicide-related thoughts and behaviors, and has a binary response (yes/no). Suicidal Ideation: a "yes" answer to any one of 5 suicidal ideation questions: Wish to be Dead, Non-specific Active Suicidal Thoughts, Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act, Active Suicidal Ideation with Some Intent to Act, without Specific Plan, Active Suicidal Ideation with Specific Plan and Intent. Suicidal Behavior: a "yes" answer to any of 5 suicidal behavior questions: Preparatory Acts or Behavior, Aborted Attempt, Interrupted Attempt, Actual Attempt (non-fatal), Completed Suicide.

    Time frame: Baseline to Day 36

  17. Expansion cohorts: Change from Baseline in Positive and Negative Syndrome Scale (PANSS)

    PANSS is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210. Higher PANSS total score means more severe outcome.

    Time frame: Baseline to Day 28

  18. Expansion cohorts: Positive and Negative Syndrome Scale (PANSS) Response at Week 4, Defined as a 20% or Greater Improvement from Baseline in PANSS Total Score

    PANSS is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210. Higher PANSS total score means more severe outcome.

    Time frame: Baseline to Day 28

  19. Expansion cohorts: Change from Baseline in Clinical Global Impression-Severity (CGI-S)

    CGI-S is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The CGI-S a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.

    Time frame: Baseline to Day 28

Secondary outcomes

  1. Dose escalation cohorts: Maximum plasma concentration (Cmax) of first HS-10380 administration

    Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.

    Time frame: Baseline to Day 36

  2. Dose escalation cohorts: Time of the Maximum Concentration (Tmax) of first HS-10380 administration

    Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.

    Time frame: Baseline to Day 36

  3. Dose escalation cohorts: Area under the concentration time curve of intervals (AUC0-τ) of first HS-10380 administration

    Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.

    Time frame: Baseline to Day 36

  4. Dose escalation cohorts: Area under the concentration time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC0-t) of first HS-10380 administration

    Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.

    Time frame: Baseline to Day 36

  5. Dose escalation cohorts: Maximum concentration at steady state (Css, max) of multiple-dose HS-10380 administration

    Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.

    Time frame: Baseline to Day 36

  6. Dose escalation cohorts: Time of the maximum concentration at steady state (Tss, max) of multiple-dose HS-10380 administration

    Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.

    Time frame: Baseline to Day 36

  7. Dose escalation cohorts: Minimum concentration at steady state (Css, min) of multiple-dose HS-10380 administration

    Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.

    Time frame: Baseline to Day 36

  8. Dose escalation cohorts: Area under the concentration-time curve at steady state (AUCss) of multiple-dose HS-10380 administration

    Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.

    Time frame: Baseline to Day 36

  9. Dose escalation cohorts: Apparent clearance at steady state (CLss/F) of multiple-dose HS-10380 administration

    Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.

    Time frame: Baseline to Day 36

  10. Dose escalation cohorts: Apparent volume of distribution at steady state (Vss/F) of multiple-dose HS-10380 administration

    Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.

    Time frame: Baseline to Day 36

  11. Dose escalation cohorts: Change from Baseline in Positive and Negative Syndrome Scale (PANSS)

    PANSS is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210. Higher PANSS total score means more severe outcome.

    Time frame: Baseline to Day 28

  12. Dose escalation cohort: Positive and Negative Syndrome Scale (PANSS) Response at Week 4, Defined as a 20% or Greater Improvement from Baseline in PANSS Total Score

    PANSS is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210. Higher PANSS total score means more severe outcome.

    Time frame: Baseline to Day 28

  13. Dose escalation cohorts: Change from Baseline in Clinical Global Impression-Severity (CGI-S)

    CGI-S is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The CGI-S a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.

    Time frame: Baseline to Day 28

  14. Expansion cohorts: Incidence and severity of adverse events(AE) ,serious AEs and AE leading to withdrawal from treatment.

    An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect.

    Time frame: Baseline to Day 43

  15. Expansion cohorts: Changes from baseline in complete blood count (CBC).

    Hematology parameters to be reported: white blood cells, red blood cells and platelets.

    Time frame: Baseline to Day 36

  16. Expansion cohorts: Changes from baseline in urinalysis.

    Parameters to be reported: protein, glucose, ketones, red blood cells, and white blood cells.

    Time frame: Baseline to Day 36

  17. Expansion cohorts: Changes from baseline in blood biochemistry test.

    Parameters to be reported: glucose, urea, serum creatinine, alanine aminotransferase, aspartate transaminase, albumin, total protein, bilirubin, and blood lipid index.

    Time frame: Baseline to Day 36

  18. Expansion cohorts: Changes from baseline in coagulation function test

    prothrombin time, activated partial thromboplastin time and international normalized ratio.

    Time frame: Baseline to Day 36

  19. Expansion cohorts: Changes from baseline in hyroid function test

    thyroxine, triiodothyronine, free triiodothyronine, free thyroxin and thyroid stimulating hormone.

    Time frame: Baseline to Day 36

  20. Expansion cohorts: Changes from baseline in serum prolactin

    Laboratory test.

    Time frame: Baseline to Day 36

  21. Expansion cohorts: Changes from baseline in blood pressure (BP)

    Vital sign.

    Time frame: Baseline to Day 36

  22. Expansion cohorts: Changes from baseline in pulse rate

    Vital sign.

    Time frame: Baseline to Day 36

  23. Expansion cohorts: Changes from baseline in body temperature

    Vital sign.

    Time frame: Baseline to Day 36

  24. Expansion cohorts: Change from baseline in body weight

    Body weight was measured in kilograms (Kg).

    Time frame: Baseline to Day 29

  25. Expansion cohorts: Change from baseline in Electrocardiogram (ECG)

    ECG parameters including heart rate, PR interval, RR interval and QTcF, etc.

    Time frame: Baseline to Day 36

  26. Expansion cohorts: Change from baseline in Simpson-Angus Scale (SAS)

    SAS is a 10-item testing instrument used to evaluate drug-related extrapyramidal syndromes. The following items are included in the SAS: gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella reflex, tremor, and salivation. Total score ranges from 0 to 40 with a higher score indicating increased severity.

    Time frame: Baseline to Day 36

  27. Expansion cohorts: Change from baseline in Abnormal Involuntary Movement Scale (AIMS)

    AIMS is a rating scale measuring involuntary movements known as tardive dyskinesia, that sometimes develop as a side effect of long-term treatment with antipsychotic medications. The AIMS score was calculated as the sum of questions 1 through 7 of the AIMS instrument, which includes assessments of involuntary movements in the face, lips, jaw, tongue, upper and lower extremities, and neck/shoulders/hips. Each item is rated on a five-point scale of severity from 0-4 with 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Total scores range from 0 to 28.

    Time frame: Baseline to Day 36

  28. Expansion cohorts: Change from baseline in Barnes Akathisia Rating Scale

    BARS is a rating scale that is administered by physicians to assess the severity of drug-induced akathisia, which is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion, as well as by actions such as rocking while standing or sitting, lifting the feet as if marching on the spot, and crossing and uncrossing the legs while sitting. The following subcategories are scored: objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness and are rated on a 4-point scale from 0-3. In addition, the global clinical assessment of akathisia uses a 6-point scale ranging from 0-5. Total score ranges from 0 to 14 with a higher score indicating increased severity.

    Time frame: Baseline to Day 36

  29. Expansion cohorts: Change from Baseline in Columbia - Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a scale capturing occurrence, severity, and frequency of suicide-related thoughts and behaviors, and has a binary response (yes/no). Suicidal Ideation: a "yes" answer to any one of 5 suicidal ideation questions: Wish to be Dead, Non-specific Active Suicidal Thoughts, Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act, Active Suicidal Ideation with Some Intent to Act, without Specific Plan, Active Suicidal Ideation with Specific Plan and Intent. Suicidal Behavior: a "yes" answer to any of 5 suicidal behavior questions: Preparatory Acts or Behavior, Aborted Attempt, Interrupted Attempt, Actual Attempt (non-fatal), Completed Suicide.

    Time frame: Baseline to Day 36

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Jun 2024, 11 months later.

Of 18 phase 1/2 interventional studies under Schizophrenia, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 70. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2023
First posted
Jul 28, 2023
StartEst.
Jul 30, 2023
Primary completionEst.
Jun 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Jul 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05964790
Responsible party
Sponsor
First posted
Jul 28, 2023
Start date
Jul 30, 2023 (estimated)
Primary completion
Jun 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Jul 28, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10380

Start the discussion